| __timestamp | Alnylam Pharmaceuticals, Inc. | Ascendis Pharma A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 19698000 |
| Thursday, January 1, 2015 | 276495000 | 40528000 |
| Friday, January 1, 2016 | 382392000 | 66022000 |
| Sunday, January 1, 2017 | 390635000 | 99589000 |
| Monday, January 1, 2018 | 505420000 | 140281000 |
| Tuesday, January 1, 2019 | 655114000 | 191621000 |
| Wednesday, January 1, 2020 | 654819000 | 260904000 |
| Friday, January 1, 2021 | 792156000 | 295867000 |
| Saturday, January 1, 2022 | 883015000 | 379624000 |
| Sunday, January 1, 2023 | 1004415000 | 413454000 |
| Monday, January 1, 2024 | 1126232000 | 307004000 |
Data in motion
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Alnylam Pharmaceuticals, Inc. and Ascendis Pharma A/S have been at the forefront of this race since 2014. Over the past decade, Alnylam has consistently outpaced Ascendis, with its R&D expenses growing by over 400% from 2014 to 2023. In 2023, Alnylam's R&D spending reached a staggering $1 billion, more than double Ascendis's $413 million. This trend highlights Alnylam's aggressive investment in pioneering RNA interference therapies. Meanwhile, Ascendis has shown a steady increase, with a notable 20-fold rise in R&D expenses since 2014, reflecting its focus on developing innovative endocrinology treatments. As these companies continue to push the boundaries of medical science, their R&D investments will be pivotal in shaping the future of healthcare.
Research and Development: Comparing Key Metrics for Amgen Inc. and Alnylam Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for argenx SE and Alnylam Pharmaceuticals, Inc.
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Genmab A/S
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Bio-Techne Corporation
Research and Development: Comparing Key Metrics for Alnylam Pharmaceuticals, Inc. and Lantheus Holdings, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.
R&D Insights: How Teva Pharmaceutical Industries Limited and Ascendis Pharma A/S Allocate Funds
Ascendis Pharma A/S vs Verona Pharma plc: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Ascendis Pharma A/S and Ionis Pharmaceuticals, Inc.
Comparing Innovation Spending: Ascendis Pharma A/S and Mesoblast Limited
Who Prioritizes Innovation? R&D Spending Compared for Ascendis Pharma A/S and Novavax, Inc.
Research and Development Investment: Ascendis Pharma A/S vs BioCryst Pharmaceuticals, Inc.